Studies of Populations Exposed to Therapeutic Medical Radiation and Other Agents

REB研究人员使用监测流行病学和最终结果计划癌症登记数据库评估所有癌症后多种癌症的风险，该数据库包括1973年至2008年诊断的200多万癌症幸存者。2006年《多重原发专论》的有趣发现被用于评估放射相关和化疗相关的二次癌症风险的个别研究。特别感兴趣的研究包括乳腺癌、霍奇金淋巴瘤、非霍奇金淋巴瘤、视网膜母细胞瘤和儿童癌症的幸存者。2012年公布了与放疗相关的第二次癌症比例的首次估计。良性妇科疾病放射治疗后的癌症-在近15,000名妇女中进行的良性妇科疾病放射治疗后的癌症死亡率，个人放射剂量数据正在更新，以评估实体瘤和白血病的风险。结果于2012年提交发表。儿童癌症幸存者研究——在14000名5年儿童癌症幸存者的队列中，我们对乳腺癌、甲状腺、唾液腺、骨、软组织和皮肤的第二原发性癌症进行了巢式病例对照研究，以评估放疗和化疗与这些癌症风险之间的关系。一项新的发现是甲状腺癌风险与先前接受烷基化剂治疗的患者暴露于低于20 Gy的甲状腺辐射有关。新的分析第二乳腺癌与既往癌症治疗和潜在效果调节剂的关系已经开始。CCSS也是研究基因-辐射相互作用潜力的独特资源和难得机会。特别值得注意的是生物标本的可获得性、关于放射和化疗剂量的高质量信息以及受照射队列的年龄小。我们目前正在进行后续新生儿全基因组关联研究

REB investigators evaluate the risks of multiple cancers following all cancers using the Surveillance Epidemiology and End Results Program cancer registry database including more than 2 million cancer survivors diagnosed from 1973 to 2008. Interesting findings from the 2006 Multiple Primary Monograph have been followed up with individual studies evaluating risk of radiation-related and chemotherapy-related second cancers. Particular studies of interest include of survivors of breast cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, retinoblastoma, and childhood cancers. In 2012 the first estimates of the proportion of second cancers related to radiotherapy were published. Cancer Following Radiotherapy for Benign Gynecologic Disorders - Cancer mortality following radiation treatment for benign gynecologic conditions in a cohort of nearly 15,000 women with individual radiation dose data is being updated to evaluate solid tumor and leukemia risk. Results were submitted for publication in 2012. Childhood Cancer Survivor Study - In a cohort of 14,000 5-year survivors of childhood cancer we performed nested case-control studies of second primary cancers of the breast, thyroid gland, salivary gland, bone, soft tissue and skin to evaluate the relationship between radiation and chemotherapy and risk of these cancers. A novel finding was that thyroid cancer risk was related to prior treatment with alkylating agents among patients exposed to radiation less than 20 Gy to the thyroid. New analyses of second breast cancers in relation to prior cancer treatment and potential effect modifiers has been initiated. The CCSS also is a unique resource and a rare opportunity in which to examine the potential for gene-radiation interaction. Particularly noteworthy are the availability of biospecimens, high quality information on doses of radiation and chemotherapy, and the young age at exposure of the cohort. We are currently performing a genome wide association study of subsequent ne